Skip to main content

Table 3 Heart rate and heart dimensions

From: Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial

  Liraglutide (n = 23) Placebo (n = 26) Mean (95% CI) changes from baseline (liraglutide vs placebo) p value
Baseline 26 week Mean (SD) change from baseline Baseline 26 week Mean (SD) change from baseline
Heart rate in bpm (SD) 72 (9) 75 (10) 4 (8) 77 (13) 76 (13) − 1 (6) 4.3 (0.2 to 8) 0.04
LV filling volume in mL (SD) 82 (17) 76 (17) − 5 (15) 74 (17) 82 (21) 7 (10) − 11 (− 18 to − 3) 0.01
LA volume index in mL/m2 (SD) 36 (8) 35 (7) − 1 (6) 32 (8) 34 (10) 1 (7) − 2 (− 6 to 2) 0.38
LVEDV in mL (SD) 147 (25) 141 (25) − 5 (14) 138 (33) 144 (38) 6 (16) − 11 (− 20 to − 2) 0.02
LVESV in mL (SD) 67 (14) 66 (14) − 0 (9) 62 (17) 63 (20) 1 (9) − 1 (− 7 to 4) 0.69
LVM in g (SD) 107 (18) 105 (18) − 2 (8) 108 (27) 110 (29) 4 (9) − 6 (− 11 to − 1) 0.03
LVMI in g/m2 (SD) 49 (6) 49 (6) − 0 (3) 50 (11) 52 (12) 2 (4) − 1.5 (−3.6 to 0.6) 0.17
LVMI/LVEDVI g/mL/m2 (SD) 0.73 (0.10) 0.75 (0.11) 0.01 (0.07) 0.79 (0.14) 0.77 (0.14) − 0.00 (0.08) 0.01 (− 0.03 to 0.06) 0.60
LV compliance (SD) 23.4 (10.4) 24.1 (8.3) 0.7 (9.7) 19.5 (8.0) 18.6 (8.2) − 0.3 (6.8) 3 (− 1 to 7) 0.14
  1. bpm beats per minute, LA left atrial, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LVM left ventricular mass index, LVMI left ventricular mass index, LVEDVI left ventricular end diastolic volume index